After buying Apellis for $5.6B, Biogen is cutting most of its pipeline work

Biogen pauses or cancels most R&D programs from its $5.6B Apellis buyout and lays off staff, keeping its focus on Empaveli and Syfovre.

Raccontata daendpoints.news